• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A primer on copay accumulators, copay maximizers, and alternative funding programs.关于共付额累积器、共付额最大化器及替代筹资计划的入门知识。
J Manag Care Spec Pharm. 2024 Aug;30(8):883-896. doi: 10.18553/jmcp.2024.30.8.883.
2
Assessment of racial and ethnic inequities in copay card utilization and enrollment in copay adjustment programs.评估种族和民族在 copay 卡使用和 copay 调整计划参与方面的不平等现象。
J Manag Care Spec Pharm. 2023 Sep;29(9):1084-1092. doi: 10.18553/jmcp.2023.23021. Epub 2023 Aug 7.
3
Web-based survey to assess the perceptions of managed care organization representatives on use of copay subsidy coupons for prescription drugs.基于网络的调查,以评估管理式医疗组织代表对使用处方药共付补贴优惠券的看法。
J Manag Care Pharm. 2013 Oct;19(8):602-8. doi: 10.18553/jmcp.2013.19.8.602.
4
Backlash Against Copay Accumulators.对共付额累积器的强烈反对。
Manag Care. 2018 Sep;27(9):15.
5
How does drug coverage vary by insurance type? Analysis of drug formularies in the United States.药物覆盖范围如何因保险类型而异?美国药品处方集分析。
Am J Manag Care. 2014 Apr;20(4):322-31.
6
Effects of prescription coinsurance and income-based deductibles on net health plan spending for older users of inhaled medications.处方共付保险和基于收入的免赔额对老年吸入药物使用者健康保险计划净支出的影响。
Med Care. 2009 May;47(5):508-16. doi: 10.1097/MLR.0b013e318190d482.
7
Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment.有和没有急性心肌梗死的患者在药物费用分担情况下他汀类药物治疗的依从性:一项基于人群的自然实验。
Circulation. 2007 Apr 24;115(16):2128-35. doi: 10.1161/CIRCULATIONAHA.106.665992. Epub 2007 Apr 9.
8
Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.药品和医疗器械:医疗保险D部分。年终问题简报。
Issue Brief Health Policy Track Serv. 2009 Jan 5:1-26.
9
Patient Cost-Sharing and Hospitalization Offsets in the Elderly.老年人的患者自付费用和住院抵消。
Am Econ Rev. 2010 Mar 1;100(1):193-213. doi: 10.1257/aer.100.1.193.
10
Small Changes or Big Ones? The Case of Limits on Prescription Drug Copayments in California.小变化还是大变化?加利福尼亚州处方药自付费用限制的案例。
Manag Care. 2018 Jul;27(7):27-29.

引用本文的文献

1
Advancing the conversation: 30 years of scholarship in managed care pharmacy.推动对话:管理式医疗药学30年学术研究
J Manag Care Spec Pharm. 2025 Jul;31(7):617-626. doi: 10.18553/jmcp.2025.31.7.617.

本文引用的文献

1
Insurance Approval Delay of Biologic Therapy Dose Escalation Associated with Disease Activity in Patients with Inflammatory Bowel Disease.生物治疗剂量升级与炎症性肠病患者疾病活动相关的保险批准延迟。
Dig Dis Sci. 2023 Dec;68(12):4331-4338. doi: 10.1007/s10620-023-08098-7. Epub 2023 Sep 19.
2
Health Insurer Strategies to Reduce Specialty Drug Spending-Copayment Adjustment and Alternative Funding Programs.健康保险公司降低专科药物支出的策略——共付额调整与替代资金计划
JAMA Intern Med. 2023 Jul 1;183(7):635-636. doi: 10.1001/jamainternmed.2023.1829.
3
Delays in Therapy Associated With Current Prior Authorization Process for the Treatment of Inflammatory Bowel Disease.炎症性肠病治疗当前预先授权流程所导致的治疗延误。
Inflamm Bowel Dis. 2023 Oct 3;29(10):1658-1661. doi: 10.1093/ibd/izad012.
4
Variation In Use And Content Of Prescription Drug Step Therapy Protocols, Within And Across Health Plans.处方药物分步治疗方案在医疗计划内和跨医疗计划使用和内容的变化。
Health Aff (Millwood). 2021 Nov;40(11):1749-1757. doi: 10.1377/hlthaff.2021.00822.
5
Refocusing Medication Prior Authorization on Its Intended Purpose.将药物预先授权重新聚焦于其预期目的。
JAMA. 2020 Feb 25;323(8):703-704. doi: 10.1001/jama.2019.21428.
6
Impact of a co-pay accumulator adjustment program on specialty drug adherence.共付额累加器调整方案对专科药物治疗依从性的影响。
Am J Manag Care. 2019 Jul;25(7):335-340.

关于共付额累积器、共付额最大化器及替代筹资计划的入门知识。

A primer on copay accumulators, copay maximizers, and alternative funding programs.

作者信息

Choi David, Zuckerman Autumn D, Gerzenshtein Svetlana, Katsivalis Katherine V, Nichols Patrick J, Saknini Marci C, Schneider Megan P, Taylor Paige, Dusetzina Stacie B

机构信息

Department of Pharmacy, University of Chicago Medicine, IL (Choi, Gerzenshtein, Katsivalis, Taylor).

Department of Pharmaceutical Services, Vanderbilt University Medical Center, Nashville, TN (Zuckerman, Nichols, Saknini, Schneider).

出版信息

J Manag Care Spec Pharm. 2024 Aug;30(8):883-896. doi: 10.18553/jmcp.2024.30.8.883.

DOI:10.18553/jmcp.2024.30.8.883
PMID:39088335
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11293768/
Abstract

Insurer or self-insured employer's plans are increasingly using copay accumulator, copay maximizer, and alternative funding programs (AFPs) to reduce plan spending on high-priced prescriptions. These programs differ in their structure and impact on patient affordability but typically decrease the insurer or self-insured employer's financial responsibility for high-priced drugs and increase the complexity of specialty medication access for patients. The aim of this primer is to describe the structure of copay accumulator, copay maximizer, and AFPs to improve understanding of these cost-shifting strategies and help clinicians and patients navigate medication access and affordability issues to minimize treatment delays or non-initiation.

摘要

保险公司或自保雇主计划越来越多地使用共付额累积器、共付额最大化器和替代资金计划(AFP)来减少高价处方药的计划支出。这些计划在其结构以及对患者可承受性的影响方面存在差异,但通常会降低保险公司或自保雇主对高价药品的财务责任,并增加患者获取专科药物的复杂性。本入门指南的目的是描述共付额累积器、共付额最大化器和AFP的结构,以增进对这些成本转移策略的理解,并帮助临床医生和患者应对药物获取和可承受性问题,以尽量减少治疗延迟或不开始治疗的情况。